Scientists at the USC Michelson Center for Convergent Bioscience and Stanford University have taken the first steps toward making a safer drug for reducing maternal mortality. (December 3, 2018)

After seeing how his mother dealt with the disease, Peter Kuhn tackles the toughest questions about cancer. Kuhn is a cancer researcher at the USC Michelson Center for Convergent Bioscience. He studies how cancer invades the human body.

A trio of USC Viterbi researchers have unlocked secrets about an engineered protein receptor, known as CAR, that makes cancer-fighting T cells more effective. Assistant Professor Stacey Finley, Professor Pin Wang and Assistant Professor Nick Graham have just published a paper that sheds light on how this new treatment works.

USC Viterbi Magazine reports that USC’s “largest, most ambitious building is bringing together real life dynamic duos.” The building has brought together engineers, scientists and doctors to solve the biggest health issues of our time. (Fall 2018)

USC Viterbi reported that Eun Ji Chung has received the NIH New Innovator Award. With over $2.4 million in funding from this NIH grant, Chung will develop a new approach to autosomal dominant polycystic kidney disease (ADPKD). (October 2, 2018)

USC Viterbi reports that researchers from the USC Viterbi School of Engineering and the Keck School of Medicine at USC have engineered peptide nanoparticles that outsmart the biological system and target kidney cells, an innovation that may prove critical to addressing chronic kidney disease. (August 22, 2018)

USC News wrote that researchers at USC have invented a device that could significantly improve care for people with hydrocephalus, a chronic condition that causes excessive fluid in the brain. (August 3, 2018)

USC Dornsife wrote that Peter Kuhn has initiated two new research projects on two types of cancer at the USC Michelson Center for Convergent Bioscience. For both, he aims to create the equivalent of a navigation tool for oncology teams to select the best treatment options for patients based on the genetic characteristics of their cancer and their own health profile. (July 17, 2018)

Trojan Family Magazine wrote that the convergence at Michelson Hall of scientists, doctors, institutions, families and philanthropists all dedicated to drug discovery and development are making the difference in finding solutions to the world’s most pressing health challenges. (July 16, 2018)

USC Viterbi reported that the USC Michelson Center for Convergent Bioscience has partnered with Agilent Technologies, a Silicon Valley-based public research, development, and manufacturing company, to establish the Agilent Center of Excellence in Biomolecular Characterization. (May 30, 2018)